pemetrexed
pemetrexed: 129 clinical trials tracked.
pemetrexed evidence translation
What we can confirm
129 tracked trials
What it means
What to watch
Prepared research question
What is verified about pemetrexed, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 36 study sponsors
Related indications
Clinical Trials (129)showing 10 most recent
A Randomized Phase II Study Evaluating Upfront SRT to All Brain Metastases Followed by Ivonescimab Plus Chemotherapy Versus Upfront Ivonescimab Plus Chemotherapy in Patients With Asymptomatic Active Brain Metastases From NSCLC
Primary endpoint: Intracranial progression-free survival based on local assessment using RANO-BM criteria
Phase I Pilot Trial of Golcadomide With Pemetrexed, Rituximab, and Dexamethasone for Relapsed and Refractory CNS Lymphomas
Primary endpoint: Safety of Golcadomide + Pemetrexed, Rituximab and Dexamethasone
A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer
Primary endpoint: Progression-Free Survival (PFS) using blinded independent central review (BICR) assessment as defined by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)
A Prospective, Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Spatially Fractionated Radiotherapy Combined With Tislelizumab and Platinum-based Doublet Chemotherapy as Induction/Conversion Therapy for Potentially Resectable Stage III Non-small Cell Lung Cancer With Bulky Disease.
Primary endpoint: Major Pathological Response (MPR) Rate
A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer
Primary endpoint: Major Pathologic response (MPR)
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion
Primary endpoint: Part 1: Number of participants who achieve Objective Response (OR)
Phase 3, Randomized, Open-Label Study of Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care as First-Line Treatment for Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Primary endpoint: Progression-Free Survival (PFS) by BICR (RECIST v1.1)
Phase II Trial Assessing 1st Line and 2nd Line Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease
Primary endpoint: 1st line part: disease Control Rate at 8 weeks
Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)
Primary endpoint: Number of Participants With Adverse Events (AEs)
A Phase II Study of Ivonescimab as Monotherapy or in Combination With Platinum/Pemetrexed Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harboring Actionable Genomic Alterations (AGAs)
Primary endpoint: Objective Response Rate (ORR) of Ivonescimab Monotherapy